Back to News
Market Impact: 0.12
INmune Bio Adds Rare Disease, Biopharma Executives Duane Clark And James Sapirstein To Board
Source: Nasdaq
Management & GovernanceHealthcare & Biotech
ImmuneBio appointed R. Duane Clark II and James Sapirstein to its board of directors, adding commercial and strategic leadership. The appointments are intended to support the late-stage immunology company's advancement of its Eb program, with no financial or clinical-development metrics disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
INMB0.35
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- A sharp stock market decline could lie around the corner, Wells Fargo warns
- FG Nexus repurchases 46% of outstanding common shares
- Indonesian Power Politics, Not Markets, Forced Out Finance Chief